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Abstract 
Objective: Endovascular intervention is commonly pursued as first-line management of 
symptomatic, long-segment superficial femoral artery (SFA) disease. The relative 
effectiveness and comparative long-term outcomes among bare metal stents (BMSs), covered 
stents (CSs), and drug-eluting stents (DESs) for long-segment SFA lesions remain uncertain. 
 
Methods: A retrospective cohort study identified patients with symptomatic SFA lesions 
measuring at least 15cm who successfully received an endovascular stent (BMS, CS, or 
DES). The outcomes were patency, patient presentation upon stent occlusion, amputation-
free survival (AFS), and all-cause mortality. Proportional hazards regressions and a 
multinomial logistic regression model were used to control for significant confounders.  
 
Results: A total of 226 procedures were analyzed (BMS: 95 [42%]; CS: 74 [33%]; DES: 57 
[25%]). There were no significant differences among the three stent types with respect to age, 
 
 
prevalence of either diabetes or end-stage renal disease, or smoking history. The median 
length of the SFA lesion varied across the cohorts (BMS: 28cm (interquartile range [IQR] 
20-30cm); CS: 26cm [IQR 20-30cm]; DES: 20cm [IQR 16-25cm]; P = .002). The unadjusted 
primary patency of BMSs at 12-, 24-, and 48-months following index stent placement was 
57%, 47%, and 44%, respectively. This is compared to 62%, 49%, and 42% for CSs, and 
81%, 66%, and 53% for DESs, respectively (log-rank P = .044). In adjusted models, 
however, there were no significant differences in primary patency among the stent types. 
Compared to CSs however, DESs were associated with improved primary-assisted patency 
(hazard ratio [HR] for patency loss: 0.35, P = .008) and secondary patency (HR: 0.32, P = 
.011). Across the entire follow-up period, stent occlusions occurred in 38 (40%) BMS cases, 
42 (57%) CSs, and 11 (19%) DESs (P < .001). Of these, acute limb ischemia (ALI) occurred 
in 2 (5%) BMS cases, 14 (33%) CSs, and 1 (9%) DES (P = .010). After adjustment, the 
relative risk of presenting with ALI as opposed to claudication was 27 times greater among 
occluded covered stents compared to bare metal stents (P = .020). There were no significant 
differences in AFS or all-cause mortality across the three cohorts. 
 
Conclusions:  For long-segment SFA lesions, DESs are associated with improved primary-
assisted and secondary patency over long-term follow-up. In the event of stent occlusion, 
covered stents confer an increased risk of acute ischemia.  
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BACKGROUND 
 
Literature Review 
 Peripheral arterial disease  
 Peripheral arterial disease (PAD) is a chronic condition that significantly impedes 
adequate circulation to the lower extremities. Caused by atherosclerosis, common PAD risk 
factors include: age, race, smoking, diabetes, hyperlipidemia, hypertension, chronic renal 
insufficiency, and genetic factors.1, 2 More recent literature has also implicated dietary 
composition, inflammatory states, infection, and environmental toxins in the pathogenesis of 
PAD.3 This becomes increasingly important as PAD is recognized as a marker for systemic 
atherosclerosis and is a coronary artery disease risk equivalent among both men and women.4  
 Though the majority of lower extremity atherosclerotic disease is asymptomatic, 
clinical manifestations of PAD range from intermittent claudication, defined as reproducible 
lower extremity muscle discomfort on exertion that is relieved by rest5, to chronic limb-
threatening ischemia (CLTI), largely identified by the presence of ischemic rest pain and/or 
tissue loss (in the form of either ulceration or gangrene). The Society for Vascular Surgery 
has developed the Lower Extremity Threatened Limb Classification System in order to 
objectively stratify a given individual’s risk of lower extremity amputation based on the 
presence of wounds, ischemia, and foot infection (WIfI).6 The WIfI classification system has 
four clinical stages (stages 1-4), each associated with an increasing risk of limb loss. 
Considering that WIfI stage 4 is associated with a 23% one-year amputation rate7, it is 
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imperative to accurately identify and characterize the severity of PAD in order provide 
therapy that maximizes an individual’s functional outcome.  
 Treatment for PAD relies on both lifestyle modification (smoking cessation and a 
structured exercise regimen) as well as medical management of concomitant hypertension, 
hyperlipidemia, and hyperglycemia.8 However, when a patient’s symptoms significantly limit 
their daily activities or persist despite medical management, revascularization is often 
recommended.1 This type of intervention, in turn, often requires treatment of the superficial 
femoral artery (SFA), the most commonly diseased artery in lower extremity PAD.9, 10 
 
 Review of relevant anatomy  
 The SFA is the primary artery supplying the lower extremity. It originates from the 
common femoral artery near the groin, traverses the length of the thigh, and crosses the 
adductor canal in the distal thigh before diving posteriorly and turning into the popliteal 
artery near the level of the knee (Figure 1). Since the popliteal artery subsequently goes on 
to supply the distal lower extremity by way of three runoff vessels, arterial flow through the 
SFA is critically important in the treatment of PAD. 
 The SFA’s anatomic location predisposes it to unique physical forces that have direct 
implications on the durability of any operative intervention performed in the area. It is a long 
artery, measuring as long as 35-40cm in some individuals. This considerable length, coupled 
with a relatively high atherosclerotic disease burden undoubtedly poses unique challenges 
and complexities to potential PAD-related treatments.10 Further, by traversing the thigh, the 
SFA is subject to external biomechanical forces (torsion, contraction/elongation, 
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 Traditional therapeutic approaches  
 Management of long-segment SFA lesions greater than 15cm in length has 
traditionally involved an open arterial bypass operation as indicated by consensus 
recommendations.1 In such a procedure, a vein or prosthetic conduit is used to connect patent 
arterial segments above and below the SFA occlusion, thereby reestablishing in-line blood 
flow to the distal lower extremity. Though this continues to represent the current gold 
standard10, the dramatic evolution of intraoperative imaging modalities and endovascular 
therapy over the last two decades has shifted practice to a minimally invasive, endovascular 
approach that confers less morbidity and faster recovery than open operations.13, 14 
 
 Endovascular stents and reported outcomes 
 Endovascular treatment modalities are vast and include numerous tools to treat 
atherosclerotic SFA lesions. These therapeutic options can largely be classified as: 1) 
percutaneous plain balloon angioplasty, or 2) angioplasty with additional scaffolding in the 
form of intraarterial endoprostheses (i.e., endovascular stents; Figure 2). Though effective 
for short, simple lesions, angioplasty has inferior patency rates when compared to stents for 
more complex disease patterns.15 Therefore, primary endovascular stenting has become a 
preferred treatment for long SFA lesions. 
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VIASTAR20 reported a 12-month primary patency rate of 71% for covered stents used in 
long-segment SFA lesions, as compared to 37% for bare metal stents. Similarly, the multi-
center, single-arm VIPER trial21 reported primary patency rates as high as 88% when the 
covered stent was optimally sized. At 36-months post-intervention, however, VIBRANT22 
reported similar patency rates between covered and bare metal stents: 24% vs. 26%, 
respectively. As with bare metal stents, the mechanism of failure of covered stents remains 
intimal hyperplasia, but localized to the stent’s edges. Therefore, even if covered stents do 
have improved short-term patency rates, any advantage seems to be extinguished within three 
years of stent placement. 
 With continued advancement of endovascular technology, yet another type of stent 
emerged in order to combat the risk of intimal hyperplasia-related in-stent occlusion. Drug-
eluting stents attempt to use local concentrations of antiproliferative agents to maintain stent 
patency.15 Until September 2018 there was only one FDA-approved drug-eluting stent 
available for use in the United States: the Zilver PTX stent (Cook Medical; Bloomington, 
IN), a self-expanding nitinol stent with a polymer-free paclitaxel coating.23 Prospective 
comparisons of drug-eluting stents to plain balloon angioplasty revealed an improvement in 
five-year primary patency rates: 66% versus 43%, respectively.24 
 
 Reporting standards for stent patency 
 With the increase in the number of studies investigating stent patency, updated 
reporting standards for the endovascular treatment of PAD were published in 2016 by the 
Society for Vascular Surgery.25 These standards used two factors in defining patency: 1) the 
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timing of re-intervention, and 2) whether the intervention was performed for in-stent 
occlusion (as opposed to stenosis). With these, three different types of patency were 
described:  
• Primary patency – “the interval from the time of the original intervention until any 
intervention designed to maintain or re-establish patency is performed”  
• Primary-assisted patency – “patency of the endovascular intervention achieved with 
the use of additional or secondary surgical or endovascular procedures, as long as 
occlusion of the primary treated site has not occurred”  
• Secondary patency – “patency obtained with the use of an additional or secondary 
surgical or endovascular procedure after occlusion occurs.”  
 
 Current limitations of the literature  
 Though there have been several prospective studies attempting to elucidate outcomes 
among these three stent types, significant gaps in the literature prevent direct comparability 
and broad generalization of the results. A significant limitation is the wide range of lesion 
lengths reported in these studies, with mean lesions measuring anywhere from 6.5cm among 
drug-eluting stents26 to 19cm among covered stents.20-22 As lesion length can confound the 
relationship between the type of stent used and its subsequent patency rate13, this difference 
undoubtedly influences the interpretation of these results. Additionally, the variation in 
follow-up time raging anywhere from 12 months to 5 years serves as yet another barrier to 
the direct comparison of these stents. Taken together, though these stents are superior to 
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balloon angioplasty alone, the relative effectiveness and comparative outcomes among bare 
metal, covered, and drug-eluting stents, particularly in long-segment SFA lesions, continue to 
remain uncertain.  
 
Public Health Significance 
 PAD is associated with significant morbidity and mortality burdens worldwide.10 
Nationally, more than 15 million people over the age of 40 are estimated to have PAD. With 
insurance claims data indicating an annual prevalence of 12% and an incidence of 3% 27, the 
management of PAD is estimated to cost between $200-400 billion per year.14 Importantly, 
the prevalence of PAD increases with age, reaching nearly 23% among Americans greater 
than 80 years of age.27 Considering that PAD is a coronary artery disease risk equivalent, it is 
not surprising that individuals with PAD also have a 2-3 times increased risk of all-cause 
mortality within three years of diagnosis.28 
 In addition to a significant risk of mortality, PAD similarly negatively impacts quality 
of life.29 Surgical intervention is performed at an estimated rate of approximately 600 per 
100,000 people30, with intermittent claudication associated with a 1% per year risk of limb 
loss1, 31 as compared to a substantially higher one-year amputation risk of 25% among CLTI 
patients.1, 32 Most striking, however, is the nearly 50% one-year mortality rate among 
Medicaid PAD patients who undergo a major lower extremity amputation.27 With such 
profoundly negative impacts on a substantial proportion of the population, identifying 
effective and durable treatment options for PAD is crucial for avoiding amputation, 
maintaining quality of life, and decreasing premature PAD-related deaths. 
10 
 
Specific Aims 
 The objective of this study was to identify pragmatic differences in clinically-relevant 
outcomes associated with the three primary stents types used in the treatment of long-
segment, atherosclerotic, superficial femoral artery (SFA) disease. The central hypothesis 
was that drug-eluting stents will have superior patency and limb preservation rates when 
compared to bare metal and covered stents. The enduring goal of this study was to identify 
the optimal endovascular treatment modality for these complex SFA lesions in an attempt to 
minimize PAD-associated morbidity. To accomplish these goals and objectives, three 
specific aims were addressed: 
 Aim 1: To assess long-term primary patency rates among bare metal, covered, and 
drug-eluting stents used for SFA lesions measuring at least 15cm in length. We hypothesized 
that drug-eluting stents will have superior primary patency rates across long-term follow-up 
of at least 12 months in duration. 
 Aim 2: To assess long-term primary-assisted patency, secondary patency, 
amputation-free survival, and all-cause mortality rates among the three stent types. We 
hypothesized that drug-eluting stents will have greater primary-assisted and secondary 
patency when compared to bare metal and covered stents. We also hypothesized that there 
will be no significant difference in either amputation-free survival or all-cause mortality. 
 Aim 3: To assess differences in patient symptomatology in the event of stent 
occlusion. We hypothesized that covered stents are associated with a greater incidence of 
acute limb ischemia at the time of stent occlusion when compared to bare metal and drug-
eluting stents.  
11 
 
METHODS 
Study Design 
 A single-center, retrospective cohort study was conducted. 
 
Study Setting 
 The setting for this study was the Michael E. DeBakey Veterans Affairs (VA) 
Medical Center in Houston, TX. 
 
Study Subjects 
 Subjects were included in the study if they: 1) were an adult (at least 18 years of age); 
2) had an endovascular stent successfully placed for a symptomatic, long-segment, 
atherosclerotic SFA lesion measuring at least 15cm in length, with technical success defined 
as residual stenosis of less than 30% on completion angiography; and 3) had the index stent 
placed between May 2008 and December 2017. Of note, “symptomatic” was defined as a 
preoperative indication of intermittent claudication, ischemic rest pain, and/or tissue loss, 
with or without concomitant infection.  
 Patients were excluded from the study if they: 1) underwent an index operation for a 
target lesion in a vessel other than the SFA; 2) required a concomitant open arterial bypass to 
address the index SFA lesion; 3) did not attain intraoperative restoration of arterial flow 
across the target lesion as evident on completion angiogram; or 4) were pregnant at the time 
of operative intervention. Patients were also excluded if the stented arterial segment crossed 
the patella and terminated in the below-knee popliteal artery. 
12 
 
Data Collection 
 Data was collected exclusively through electronic medical review and data 
abstraction. Prospective data was not collected, no biological specimens were obtained, and 
no patients were contacted for this retrospective cohort study.  
 The exposure of interest was the type of stent used to treat the long-segment SFA 
lesion: bare metal, covered, or drug-eluting. The primary outcome of interest was primary 
patency. Secondary outcomes of interest included: primary-assisted patency, secondary 
patency, interventions required to maintain patency, patient symptomatology in the event of 
stent occlusion, amputation-free survival (defined as survival without a major lower 
extremity amputation proximal to the ankle), and all-cause mortality. Stent occlusion was 
primarily determined by duplex ultrasonography, computed tomography scan, or 
angiography showing no flow through the stent. Patency was determined based on definitions 
provided by the Society for Vascular Surgery reporting standards.25  Additionally, baseline 
data on the following pre-operative confounders was collected within six months of stent 
placement: demographics, comorbidities, medication use, and smoking history (specific 
variables are included in Table I and Table II). 
 
Data Handling 
 All data collected through electronic medical review and data abstraction were 
protected by robust firewalls and institutional computers. Additionally, the data folders 
further restricted access to those that were cleared to view the data (i.e., the principal 
investigator and research staff). 
13 
 
Data Analysis 
 Continuous variable distributions were visualized and assessed for normality. 
Descriptive statistics among the three cohorts (bare metal, covered, and drug-eluting stents) 
were presented and compared using either analysis of variance (ANOVA) or the non-
parametric Kruskal-Wallis test. A Bonferroni correction was applied when assessing pairwise 
comparisons among the three cohorts. Proportions for categorical variables were compared 
using Pearson’s chi-square test or Fisher’s exact test. Kaplan-Meier survival estimates were 
used to assess unadjusted patency rates (including primary, primary-assisted, and secondary 
patency) and amputation-free survival. Cox proportional hazards regression models were 
used to control for clinically and statistically significant confounders. An adjusted 
multinomial logistic regression model was also used to assess patient symptomatology in the 
event of stent occlusion. Statistical significance was set at a two-sided alpha of 0.05. All 
statistical analyses were performed using Stata 14.0 (StataCorp; College Station, TX). 
 
Human Subjects and Safety Considerations  
 This study was approved by the Baylor College of Medicine Institutional Review 
Board as well as the VA Research and Development Committee. As requested by the 
UTHealth Committee for Protection of Human Subjects, a SMART IRB reliance agreement 
was also established between Baylor College of Medicine (the lead site) and UTHealth. 
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JOURNAL ARTICLE 
Long-Term Outcomes after Endovascular Stent Placement for Long-Segment 
Superficial Femoral Artery Lesions 
 
Journal of Vascular Surgery 
 
 
INTRODUCTION 
 
Complex, long-segment atherosclerotic disease of the superficial femoral artery (SFA) is a 
persistently challenging clinical dilemma.1 Based on consensus recommendations, this 
pattern of disease has traditionally been managed by surgical revascularization.2 Currently, 
however, with the continued evolution of therapeutic capabilities, an endovascular approach 
is frequently pursued even for complex femoropopliteal disease.3  
 
In the setting of this increased technical feasibility, there is relatively limited data on 
outcomes following primary stent placement for long-segment SFA disease, and there is even 
less data available that directly compares the different types of stents routinely used for this 
indication.4, 5 Since the sustained durability of plain balloon angioplasty is limited in complex 
lesions5, 6, addressing this gap in the literature will assist in defining the specific role 
endovascular stents have in managing long-segment SFA disease. 
 
The objective of this study was to assess the comparative effects of bare metal, covered, and 
drug-eluting stents on clinical outcomes for the treatment of long-segment SFA disease. 
15 
 
METHODS 
Patient population and eligibility. A single-center, retrospective cohort study was 
performed. Adult patients at the Michael E. DeBakey VA Medical Center were included in 
the study if they successfully received an endovascular SFA stent for an atherosclerotic 
segment measuring at least 15cm in length between May 2008 and December 2017. 
Technical success was defined as reestablishment of SFA patency with flow across the target 
lesion with less than 30% residual stenosis on completion angiography.7 Cases were 
excluded if the stented segment traversed the level of the patella and terminated in the below-
knee popliteal artery. This study was approved by the Veterans Affairs Research and 
Development Committee as well as the Baylor College of Medicine Institutional Review 
Board. 
 
Exposure of interest. The cases were categorized based on the type of index stent used to 
treat the lesion: 1) self-expanding nitinol bare metal stents (BMSs), 2) covered stents (CSs), 
or 3) drug-eluting stents (DESs). When deploying a CS across a lesion, care was taken to 
preserve collateral vessels measuring more than 3mm in diameter8, and oversizing the stent 
was avoided.9, 10 The CSs were self-expanding nitinol stents covered on their luminal surface 
with heparin-bonded, expanded polytetrafluoroethylene (GORE VIABAHN Endoprosthesis; 
W. L. Gore and Associates, Inc.; Flagstaff, AZ). The DESs were self-expanding nitinol stents 
with a polymer-free paclitaxel coating (Zilver PTX; Cook Medical; Bloomington, IN). 
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Outcomes. The primary outcome was primary patency. Restenosis and occlusion were 
largely documented by duplex ultrasonography, computed tomography scan, or digital 
subtraction angiography. Secondary outcomes included: primary-assisted patency, secondary 
patency, target lesion revascularization (TLR; defined by the first endovascular or open 
reintervention on the target lesion), acuity of patient presentation in the event of stent 
occlusion, amputation-free survival (AFS; defined as postoperative survival without a major 
lower extremity amputation proximal to the ankle), and all-cause mortality. AFS was 
restricted to patients who initially presented with chronic limb-threatening ischemia (CLTI, 
defined as ischemic rest pain or tissue loss). Patency and TLR were defined in accordance 
with the Society for Vascular Surgery reporting standards7, with estimates over time reported 
among the entire cohort starting at the time of stent placement.9, 11  
 
Confounding variables. Demographic data, preoperative comorbidities, and relevant 
perioperative factors were collected. Specifically, models controlled for SFA lesion length, 
runoff, CLTI on initial presentation, diabetes, end-stage renal disease, smoking history, 
serum albumin, relevant medication use (aspirin, statin, clopidogrel), sex, and age8, 12-14. 
Analyses of outcomes related to mortality were additionally adjusted for clinically relevant 
comorbidities presented in Table 1.   
 
Statistical analysis.  Continuous variable distributions were visualized and assessed for 
normality. Descriptive statistics among the three cohorts were compared using either analysis 
of variance (ANOVA) or the non-parametric Kruskal-Wallis test for continuous variables. A 
17 
 
Bonferroni correction was applied when assessing pairwise comparisons among the three 
cohorts. Proportions for categorical variables were compared using Pearson’s chi-squared 
test or Fisher’s exact test. Kaplan-Meier survival estimates were used for time-to-event 
analyses, and unadjusted differences between groups were tested using the log-rank test. 
Multivariable Cox proportional hazards regressions were used to control for clinically and 
statistically significant confounders. For outcomes related to patency, hazard ratios were 
obtained that reflected the adjusted association between stent type and loss of patency. An 
adjusted multinomial logistic regression model was used to assess patient presentation in the 
event of stent occlusion. Statistical significance was set at a two-sided alpha of 0.05. All 
statistical analyses were performed using Stata 14.0 (StataCorp; College Station, TX). 
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RESULTS  
Descriptive characteristics. A total of 205 patients accounted for 226 SFA lesions that were 
included in the analysis. 95 (42%) lesions were treated with BMSs, 74 (33%) with CSs, and 
57 (25%) with DESs. The cohort treated with DESs had a comparatively lower proportion of 
men (P = .015), a greater prevalence of stroke (P = .007), and a lower serum albumin level (P 
= .010). There were no significant differences across cohorts in mean age, prevalence of 
either diabetes or end-stage renal disease, or smoking history. De novo atherosclerotic lesions 
comprised the vast majority of the lesions treated across all cohorts (BMS: 93 [98%], CS: 66 
[89%], DES: 51 [90%], P = .107). Descriptive characteristics of the three cohorts are 
presented in Table I. 
 
A greater proportion of DESs were placed for an indication of CLTI (BMS: 39%, CS: 31%, 
DES: 67%, P < .001), and the three cohorts varied with respect to the distribution of runoff 
vessels (P = .014). The median lesion length treated in this analysis was 25cm, but when 
compared across cohorts, there were differences present in both lesion length (P = .002) and 
follow-up times (P < .001). During index stent placement, coexisting iliac lesions were 
treated endovascularly in 10 (11%) BMS cases, 10 CS cases (14%), and 9 (16%) DES cases 
(P = .629). Common femoral artery endarterectomy was performed concomitantly in three 
(4%) CS cases, and in three (5%) DES cases. Perioperative details are presented in Table II. 
 
Patency. A total of 113 (50%) cases maintained primary patency over the course of the study 
(BMS: 44 [46%], CS: 28 [38%], DES: 41 [72%], P < .001; Table III). The unadjusted 
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Kaplan-Meier estimates for primary patency at 12-, 24-, and 48-months were 57%, 47%, and 
44% for the BMS cohort; 62%, 49%, 42% for CSs; and 81%, 66%, 53% for DESs, 
respectively (P = .044; Figure 1). In the adjusted model, there was no statistical association 
between stent type and primary patency (Table IV). 
 
The unadjusted 12-, 24-, and 48-month Kaplan-Meier estimates for primary-assisted patency 
were 68%, 63%, and 60% for BMSs; 67%, 51%, and 45% for CSs; and 89%, 79%, and 60% 
for DESs, respectively (P = .004; Supplemental Figure 1). The corresponding estimates for 
secondary patency were 74%, 69%, and 66% for BMSs; 75%, 59%, and 51% for CSs; and 
89%, 81%, and 74% for DESs (P = .011; Supplemental Figure 2). After adjustment, DESs 
had a significantly improved primary-assisted patency (HR for patency loss: 0.35, P = .008) 
and secondary patency (HR for patency loss: 0.32, P=.011; Table IV) compared to CSs.  
 
Target lesion revascularization. Across the study’s follow-up, a total of 83 (Table III) 
stented lesions collectively required 84 endovascular (BMS: 31/84 [37%], CS: 42/84 [50%], 
DES: 11/84 [13%]) and 39 open (BMS: 14/39 [36%], CS: 23/39 [59%], DES: 2/39 [5%]) 
revascularization attempts. The vast majority of both endovascular (76/84 [90%]) and open 
(32/39 [82%]) reinterventions occurred within 18 months of initial stent placement. 
 
The unadjusted Kaplan-Meier estimates for freedom from TLR at 12-, 24-, and 48-months 
were 72%, 64%, and 61% for BMSs; 71%, 59%, and 54% for CSs; 87%, 77%, and 64% for 
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DESs, respectively (P = .042; Supplemental Figure 3). After adjustment, however, there 
was no significant association between stent type and TLR (Table IV). 
 
Presentation upon stent occlusion. Stent occlusions occurred in 38 (40%) lesions treated 
with BMSs, 42 (57%) CSs, and 11 (19%) DESs (P < .001). Details of patient presentation at 
the time of stent occlusion are presented in Table III. In particular, the unadjusted rate of 
ALI was significantly different among the stent types (BMS: 5%, CS: 33%, DES: 9%; P = 
.010). Among the cases with ALI, eight (47%) required an open arterial bypass of the target 
lestion, all of whom were in patients initially treated with CSs. Additionally, eight (47%) 
individuals who developed ALI subsequently required a major lower extremity amputation, 
with six (75%) of these amputations in patients with CSs. After adjustment, the relative risk 
(RR) of presenting with ALI as opposed to claudication was 27 times greater among 
occluded covered stents compared to bare metal stents (P = .020; Table V).  Compared to 
other stents, DESs were not associated with a significantly increased risk of either ALI or 
ischemic rest pain/tissue loss in the event of stent occlusion. 
 
 
Amputation-free survival. Among patients with an operative indication of CLTI, there was 
a total of 18 (18%) major lower extremity amputations (Table III). The unadjusted 12-, 24-, 
and 48-month Kaplan-Meier estimates for AFS were 58%, 47%, and 44% for BMSs; 83%, 
69%, and 34% for CSs; and 70%, 70%, and 59% for DESs, respectively (P = .528; Figure 2). 
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In the adjusted model, there were no associations between stent type and AFS in patients 
with CLTI (Table IV). 
 
Of the 128 SFA lesions treated in patients with claudication, there were a total of seven 
(5.5%) major lower extremity amputations, all of which occurred in the CS cohort. Further, 
with respect to the timing of limb loss, four of these seven (57%) amputations occurred more 
than 12 months after the SFA was initially stented. 
 
All-cause mortality. Among all patients, 42 (46%) individuals with BMSs, 30 (43%) with 
CSs, and 10 (19%) with DESs (P = .003; Table III) died during the follow-up period. The 
unadjusted Kaplan-Meier survival estimates at 12-, 24-, and 48-months were 90%, 80%, and 
77% for BMSs; 94%, 87%, and 72% for CSs; and 85%, 85%, and 77% for DESs, 
respectively (P = .999; Figure 3). After adjustment, there was no significant association 
between the stent type and all-cause mortality (Table IV). This association was further 
maintained when DESs were compared to all other stents collectively (HR 0.57, 95% CI 
0.25-1.34, P = .199). 
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DISCUSSION  
In this study, we directly compared the long-term outcomes of bare metal, covered, and drug-
eluting stents in the treatment of symptomatic, long-segment SFA lesions measuring at least 
15cm in length. After robust adjustment for clinically and statistically significant 
confounders, our results did not identify a significant difference among these stent types with 
respect to long-term primary patency, TLR, or all-cause mortality when used to treat 
complex SFA disease. DESs appear to have improved primary-assisted and secondary 
patency across long-term follow-up, and though there is not a difference among the stents 
with respect to amputation-free survival, occlusion of covered stents is associated with a 
significantly increased risk of acute ischemia relative to bare metal stents.  
 
Despite landmark trials studying these outcomes, considerable gaps in the literature prevent 
direct comparison and generalization of the results to long SFA lesions. A significant 
limitation is the wide range of lesion lengths reported in these studies, with mean lesions 
measuring anywhere from 6.5cm among drug-eluting stents13 to 19cm among covered 
stents.4, 5, 9 Since the cumulative length of the index lesion can influence relevant outcomes14, 
this difference undoubtedly impacts the interpretation of these studies relative to one another. 
Additionally, the variation in preoperative symptoms, study design, eligibility criteria, 
outcome definitions, and reported follow-up all serve as additional barriers to the direct 
comparison of these results.6, 15 Our analysis attempts to provide a head-to-head assessment 
among these widely used endovascular prostheses, thereby helping to define the pragmatic 
role of these stents when specifically used in long-segment SFA lesions. 
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The unadjusted 12-month primary patency estimates for BMSs, CSs, and DESs in this 
analysis were 57%, 62%, and 81%, respectively. When compared to the available literature 
that either exclusively investigates long-segment SFA disease or provides sub-group analysis 
of complex lesions, 12-month primary patency for these stents ranges from 37-83% for 
BMSs5, 16, is reported to be 71% for CSs5, and ranges from 53-78% for DESs.17, 18 Though 
our observed primary patency for CSs appears to be lower than that in the literature (62% vs. 
71%)5, it actually compares favorably to a 12-month primary patency of 53% reported in the 
VIBRANT trial which included lesions with a mean length of 18cm.  
 
After adjustment for relevant confounders, there was no statistically significant difference in 
primary patency rates among the three stent types included in this analysis. In contrast, DESs 
appear to provide an improvement in primary-assisted and secondary patency when 
compared to CSs in our study. Interestingly, this association with secondary patency is not 
readily evident from the literature if only assessing 12-month Kaplan-Meier estimates which 
actually suggest the opposite: higher patency rates in CSs (90-92%5, 9) compared to DESs 
(80-88%17, 19). Not only does this underscore the advantage of direct comparison for these 
stents, but it also highlights the role of appropriate risk adjustment when interpreting patency 
rates over time.   
 
In this study, we present Kaplan-Meier estimates through four years of follow-up for DESs 
and five years for BMSs and CSs. Based on these rates and corresponding confidence 
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intervals, patency generally appears relatively stable beyond 18 months after SFA stenting. 
Among DESs used to treat shorter lesions, similar trends are reported in the literature for 
primary patency over a five-year follow-up period.20 Though this has also been implied for 
long-segment lesions, patency for complex disease patterns beyond 24 months is infrequently 
reported.4, 16 Considering that the vast majority of the reinterventions in this study 
correspondingly occurred within the first 1-2 years, these findings underscore the importance 
of routine follow-up during the first 18 months after a complex SFA lesion is treated.2 
 
In the event of stent occlusion, those treated with covered stents were significantly more 
likely to present with ALI as opposed to claudication when compared to bare metal stents. 
This was true even after adjustment for baseline comorbidities, medications, lesion length, 
runoff, and preoperative CLTI. These findings support similar observations reported by 
others, 12, 21, 22 and may be due to the mechanism by which stents fail. In the case of BMSs, 
for example, in-stent restenosis occurs gradually as a result of neointimal hyperplasia 
throughout the length of the stent.4, 5, 23 In CSs, however, this proliferative reaction is located 
at the stent’s edges, a physiological consideration that can cause thrombosis of the stent graft 
over a relatively short period of time, resulting in an acute presentation.24, 25  
 
In randomized controlled trials, no differences were noted in amputation rates between BMSs 
and either CSs or DESs.4, 5, 13  Similarly, we did not observe a difference in either unadjusted 
or adjusted amputation-free survival estimates among patients with CLTI. With respect to 
mortality, however, meta-analytic pooled data (n = 4432 cases; 11% with CLTI) indicates 
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that five-year all-cause death is significantly  increased in patients treated with paclitaxel-
coated devices (including both balloons and stents).26 Another nationwide analysis of claims 
data (n = 16,560; 51% CLTI), however, shows no association between paclitaxel-coated 
devices and all-cause mortality.27 Though our multivariable analysis (which controlled for 
comorbidities, medications, and initial presentation) did not reveal a difference in all-cause 
mortality in this particular patient population with long SFA lesions, dedicated investigation 
is necessary in order to accurately assess long-term survival. 
 
The limitations of this study must also be considered. Compared to the other stent types, the 
DES cohort had a smaller sample size with shorter follow-up. Though this is expected given 
that DESs are a relatively newer technology, this inherently decreases the relative accuracy 
of the cohort’s long-term outcome estimates. This is most evident in our analyses of AFS as 
restricted to patients with CLTI, and clinical presentation in the event of stent occlusion. This 
may have additionally prevented us from identifying a significant difference in primary 
patency across the cohorts. Additionally, with three exposure groups and the absence of 
prospective randomization, there were statistically significant baseline and perioperative 
differences among the cohorts. Even with robust risk adjustment that accounted for not only 
these differences, but other clinically relevant confounders as well, the retrospective nature of 
the study still imparts the possibility of residual confounding. Further, given our patient 
population, these results are not directly generalizable to women. 
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CONCLUSION 
For long-segment SFA lesions treated with endovascular stents, drug-eluting stents appear to 
have improved primary-assisted and secondary patency rates as compared to covered stents. 
The majority of open and endovascular reinterventions occur within 18 months after stent 
placement, which warrants routine follow-up during this time period. Though there is no 
difference in amputation-free survival among patients with preoperative CLTI, covered stents 
have an increased risk of presenting with acute limb ischemia in the event of stent occlusion, 
an association that can influence decision-making algorithms and patient counseling.   
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Tables 
Table I. Descriptive characteristics and comorbidities of cases included in the study 
 
Variable Overall (N=226) 
Bare Metal
(n=95) 
Covered 
(n=74) 
Drug-Eluting 
(n=57) P-value 
Age, years (mean, SD) 65.0 (7.1) 65.4 (7.7) 64.0 (6.2) 65.8 (6.9) .277 
Male 221 (97.8) 94 (99.0) 74 (100) 53 (93.0) .015 
Race/ethnicity      
Caucasian 143 (63.3) 56 (59.0) 54 (73.0) 33 (57.9) 
.125 
African 
American 
59 (26.1) 31 (32.6) 13 (17.6) 15 (26.3) 
Other* 24 (10.6) 8 (8.4) 7 (9.5) 9 (15.8) 
BMI, kg/m2  
(mean, SD) 
28.2 (5.1) 27.7 (4.7) 29.0 (5.4) 28.1 (5.2) .279 
Hypertension 207 (91.6) 84 (88.4) 70 (94.6) 53 (93.0) .325 
Hyperlipidemia 175 (77.4) 72 (75.8) 59 (79.7) 44 (77.2) .830 
CAD 109 (48.2) 40 (42.1) 38 (51.4) 31 (54.4) .275 
CHF 36 (15.9) 17 (17.9) 10 (13.5) 9 (15.8) .742 
Myocardial infarction 37 (16.4) 19 (20.0) 13 (17.6) 5 (8.8) .183 
CVA 23 (10.2) 7 (7.4) 4 (5.4) 12 (21.1) .007 
Diabetes  123 (54.4) 56 (59.0) 33 (44.6) 34 (59.7) .117 
Current smoking 112 (49.6) 45 (47.4) 42 (56.8) 25 (43.9) .293 
Past smoking  83 (36.7) 42 (44.2) 25 (33.8) 16 (28.1) .111 
COPD 33 (14.6) 15 (15.8) 10 (13.5) 8 (14.0) .908 
ESRD 3 (1.3) 2 (2.1) 0 1 (1.8) .480 
Albumin, g/dL  
    (median, IQR) 
3.7  
(3.3-3.9) 
3.7  
(3.3-3.9) 
3.7  
(3.5-4.0) 
3.5  
(2.9-3.8) .010 
Preoperative 
medications 
     
Statin  168 (74.3) 79 (83.2) 47 (63.5) 42 (73.7) .015 
Aspirin 149 (65.9) 69 (72.6) 44 (59.5) 36 (63.2) .176 
Clopidogrel 70 (31.0) 22 (23.2) 25 (33.8) 23 (40.4) .070 
Warfarin 9 (4.0) 5 (5.3) 3 (4.1) 1 (1.8) .626 
 
Abbreviations: BMI, body mass index; CAD, coronary artery disease; CHF, congestive heart 
failure; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident;  
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ESRD, end-stage renal disease; IQR, interquartile range; SD, standard deviation 
Note: Unless otherwise specified, variables are presented as n (%) 
*Includes those categorized as Hispanic or Native American 
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Table II. Perioperative characteristics of cases included in the study 
 
Variables Overall (N=226) 
Bare Metal 
(n=95) 
Covered 
(n=74) 
Drug-
Eluting 
(n=57) 
P-value 
Indication      
Claudication 128 (56.6) 58 (61.1) 51 (68.9) 19 (33.3) 
<.001 Rest pain 24 (10.6) 3 (3.2) 9 (12.2) 12 (21.1) 
Tissue loss 74 (32.7) 34 (35.8) 14 (18.9) 26 (45.6) 
ABI (mean, SD) 0.64 (0.22) 0.66 (0.19) 0.65 (0.25) 0.58 (0.22) .146 
Toe pressure, mmHg 
(mean, SD) 
45.6 (26.2) 47.3 (23.5) 50.5 (28.8) 36.1 (24.3) .015 
WIfI Stage      
Stage 1 77 (37.8) 31 (36.5) 29 (43.3) 17 (32.7) 
.135 
Stage 2 82 (40.2) 33 (38.8) 31 (46.3) 18 (34.6) 
Stage 3 27 (13.2) 13 (15.3) 5 (7.5) 9 (17.3) 
Stage 4 18 (8.8) 8 (9.4) 2 (3.0) 8 (15.4) 
Runoff vessels      
1 82 (36.3) 40 (42.1) 16 (21.6) 26 (45.6) 
.014 2 83 (36.7) 31 (32.6) 37 (50.0) 15 (26.3) 
3 59 (26.1) 23 (24.2) 20 (27.0) 16 (28.1) 
Lesion length, cm 
(Median, IQR) 
25 (20-30) 28 (20-30) 26 (20-30) 20 (16-25) .002 
Number of stents  
(Mean, SD) 
3.2 (1.1) 3.0 (1.1) 3.1 (0.9) 3.4 (1.1) .125 
Stent diameter, mm 
(Median, IQR) 
6.0 (6.0-
6.6) 
6.4 (6.0-6.8)
5.8 (5.6-
6.0) 
6.2 (6.0-
6.5) <.001 
Operative time, hr 
(Median, IQR) 
1.9 (1.4-
2.3) 
1.7 (1.3-2.2)
1.9 (1.4-
2.4) 
2.0 (1.7-
2.4) .007 
Operative EBL, mL 
(Median, IQR) 
25 (20-30) 25 (20-30) 25 (20-50) 20 (20-35) .099 
LOS, days  
(Median, IQR) 
1 (0-1) 0 (0-1) 1 (0-1) 1 (0-3) .005 
Follow-up time, mo 
(Median, IQR) 
55 (20-88) 67 (43-88) 82 (37-107) 20 (13-32) <.001 
 
Abbreviations: ABI, ankle-brachial index; EBL, estimated blood loss; hr, hours;  
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IQR, interquartile range; LOS, hospital length of stay; mo, months; SD, standard deviation;  
WIfI, wound, ischemia, foot infection classification 
Note: Unless otherwise specified, variables are presented as n (%) 
Missing observations: 22 missing observations in the WIfI Stage variable 
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Table III. Unadjusted event rates for postoperative outcomes across the entire follow-up period 
 
Outcome Overall 
(N=226) 
Bare Metal 
(n=95) 
Covered 
(n=74) 
Drug-Eluting
(n=57) 
P-value 
Patency      
Primary  113 (50.0) 44 (46.3) 28 (37.8) 41 (71.9) <.001 
Primary-assisted  135 (59.7) 57 (60.0) 32 (43.2) 46 (80.7) <.001 
Secondary  147 (65.0) 62 (65.3) 37 (50.0) 48 (84.2) <.001 
Target lesion revascularization 83 (36.7) 35 (36.8) 37 (50.0) 11(19.3) .001 
Symptom at stent occlusion2      
Claudication 38/91 (41.8) 16/38 (42.1) 18/42 (42.9) 4/11 (36.4) 
.010 Rest pain or Tissue loss 34/91 (37.4) 18/38 (47.4) 10/42 (23.8) 6/11 (54.5) 
ALI 17/91 (18.7) 2/38 (5.3) 14/42 (33.3) 1/11 (9.1) 
Major amputation3 18/98 (18.4) 11/37 (29.7) 2/23 (8.7) 5/38 (13.2) .070 
All-cause mortality4 82/205 (40.0) 42/91 (46.2) 30/70 (42.9) 10/53 (18.9) .003 
 
Abbreviations: ALI, acute limb ischemia 
1Event rates related to patency reflect the number of cases that maintained patency throughout the entire follow-up period. 
2Describes acuity of patient presentation in the event of stent occlusion. The denominators represent the total number of stent 
occlusions over the entire follow-up period. Two individuals with bare metal stents were asymptomatic at the time of stent 
occlusion, identified during noninvasive ultrasound surveillance. 
3Major amputations restricted to patients with a preoperative indication of CLTI. 
4All-cause mortality reported with respect to the number of patients, as opposed to the number of cases. 
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Table IV. Adjusted associations between stent type and postoperative long-term outcomes 
 
Outcome 
CS compared to BMS* DES compared to BMS* DES compared to CS* 
HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value 
Loss of patency1          
Primary patency 1.04 0.66-1.64 .849 0.57 0.29-1.12 .102 0.54 0.28-1.05 .071 
Primary-assisted patency 1.53 0.92-2.53 .100 0.54 0.24-1.21 .133 0.35 0.16-0.76 .008 
Secondary patency 1.53 0.88-2.65 .128 0.49 0.20-1.21 .122 0.32 0.13-0.77 .011 
Target lesion revascularization 1.41 0.84-2.35 .195 0.89 0.40-1.96 .772 0.63 0.30-1.34 .233 
Amputation-free survival2 0.64 0.24-1.73 .378 0.49 0.19-1.27 .141 0.76 0.23-2.52 .657 
All-cause mortality 1.11 0.53-2.33 .782 0.60 0.24-1.50 .274 0.54 0.21-1.39 .201 
 
*Denotes the reference stent type 
1Hazard ratios for patency reflect the associations between stent type and the loss of patency over time. 
2Amputation-free survival restricted to patients with a preoperative indication of CLTI. Hazard ratios reflect the association 
between stent type and having a major amputation or dying over time. 
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Table V. Adjusted association between stent type and patient presentation in the event of stent occlusion 
 
Clinical Presentation 
CS compared to BMS* DES compared to BMS* DES compared to CS* 
RRR 95% CI P-value RRR 95% CI P-value RRR 95% CI P-value 
Claudication Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. 
Rest pain or tissue loss 0.64 0.14-2.89 .558 0.56 0.07-4.42 .578 0.87 0.09-8.33 .906 
ALI 26.6 1.67-423.0 .020 13.3 0.17-1020 .243 0.50 0.02-15.5 .692 
 
*Denotes the reference stent type 
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Figures 
Figure 1. Unadjusted Kaplan-Meier estimates for primary patency by stent type 
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Figure 2. Unadjusted Kaplan-Meier estimates for amputation-free survival by stent type, 
restricted to patients initially presenting with CLTI 
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Figure 3. Unadjusted Kaplan-Meier survival estimates by stent type among the entire cohort 
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Supplemental Figure 1. Unadjusted Kaplan-Meier estimates for primary-assisted patency by 
stent type 
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Supplemental Figure 2. Unadjusted Kaplan-Meier estimates for secondary patency by stent 
type 
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Supplemental Figure 3. Unadjusted Kaplan-Meier estimates for freedom from target lesion 
revascularization (TLR) by stent type 
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